Prasad Menon - Dr Reddys Lead Non-Executive Independent Director

RDY Stock  USD 72.31  0.49  0.67%   

Director

Mr. Prasad Raghava Menon serves as Lead NonExecutive Independent Director of the Company. Mr. Prasad R Menon is a former Managing Director of Tata Chemicals Limited and Tata Power Company Limited. Prior to joining Tata, he was Director Technical of Nagarjuna Fertilisers and Chemicals Limited. He has over 40 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry. Mr. Menon holds directorship in Singapore Tourism Board and Sanmar Group Advisory Board. Mr. Menon holds a chemical engineering degree from the Indian Institute of Technology, Kharagpur, India. since 2017.
Age 74
Tenure 7 years
Address 8-2-337, Road No. 3, Hyderabad, India, 500034
Phone91 40 4900 2900
Webhttps://www.drreddys.com

Dr Reddys Management Efficiency

The company has Return on Asset of 0.1238 % which means that on every $100 spent on assets, it made $0.1238 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2139 %, implying that it generated $0.2139 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.38 in 2024, whereas Return On Assets are likely to drop 0.09 in 2024. At this time, Dr Reddys' Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 15.4 B in 2024, whereas Total Assets are likely to drop slightly above 206.1 B in 2024.
The company has 13.47 B in debt with debt to equity (D/E) ratio of 0.12, which may show that the company is not taking advantage of profits from borrowing. Dr Reddys Laboratories has a current ratio of 1.94, which is typical for the industry and considered as normal. Debt can assist Dr Reddys until it has trouble settling it off, either with new capital or with free cash flow. So, Dr Reddys' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dr Reddys Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RDY to invest in growth at high rates of return. When we think about Dr Reddys' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Heidi KunzAgilent Technologies
66
Willard DereSeres Therapeutics
64
Martha DemskiEquillium
65
Richard KenderSeres Therapeutics
62
Scott MorensteinMadrigal Pharmaceuticals
38
David MilliganMadrigal Pharmaceuticals
77
Stephen ConnellyEquillium
42
Donald KufeMadrigal Pharmaceuticals
69
Arturo Testa23Andme Holding Co
37
Robert HerboldAgilent Technologies
74
Kurt GravesSeres Therapeutics
50
Robert WilsonMadrigal Pharmaceuticals
75
Ettore Artioli23Andme Holding Co
N/A
Paul ClarkAgilent Technologies
72
Anders Forseback23Andme Holding Co
N/A
Mark PruzanskiEquillium
50
Dennis AusielloSeres Therapeutics
72
George ScangosAgilent Technologies
72
Dow WilsonAgilent Technologies
61
John FisherEquillium
60
AnnChristine Hvittfeldt23Andme Holding Co
49
Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 24795 people. Dr Reddys Laboratories (RDY) is traded on New York Stock Exchange in USA. It is located in 8-2-337, Road No. 3, Hyderabad, India, 500034 and employs 25,863 people. Dr Reddys is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Dr Reddys Laboratories Leadership Team

Elected by the shareholders, the Dr Reddys' board of directors comprises two types of representatives: Dr Reddys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RDY. The board's role is to monitor Dr Reddys' management team and ensure that shareholders' interests are well served. Dr Reddys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dr Reddys' outside directors are responsible for providing unbiased perspectives on the board's policies.
MARC KIKUCHI, Chief Executive Officer, North America Generics
Venkata MBA, CEO Council
Leo Puri, Non-Executive Independent Director
Sandeep Poddar, Compliance Officer, Company Secretary
Satish Reddy, Co-Chairman of the Board
Kedar Upadhye, IR Contact Officer
Samiran Das, Executive Vice President Head - FTO and GGPM
Patrick Aghanian, Chief Executive Officer, European Generics
Amit Biswas, Executive Vice President - Integrated Product Development
Ravi Bhoothalingam, Non-Executive Independent Director
Sanjay BTech, Global VP
Prasad Menon, Lead Non-Executive Independent Director
K Rao, Sr. Vice President & Head – Chemical Technical Operations (CTO)
K Krishnan, Additional Independent Director
Shikha Sharma, Non-Executive Independent Director
Omkar Goswami, Non-Executive Independent Director
Bharat Doshi, Non-Executive Independent Director
Gunupati BE, MD CoChairman
Raymond Vre, Global Head of Biologics
Raghav Chari, Senior Vice President - Proprietary Products
Bruce Carter, Non-Executive Independent Director
Umang Vohra, Executive Vice President Head - North America Generics
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets)
Parag Agarwal, Chief Financial Officer - Designate
Cartikeya Reddy, Senior Vice President Head - Biologics
Archana Bhaskar, Chief Human Resource Officer
Erez MBA, CEO Council
MS BTech, Chairman Council
Deepak Sapra, Global Head of Pharmaceutical Services and Active Ingredients
Penny Wan, Additional Independent Director
G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director
P Yugandhar, Global Head of Supply Chain
Hans Hasler, Additional Independent Director
Sauri Gudlavalleti, Global Head of Integrated Product Development Organization
YUGANDHAR PUVVALA, Global Head of Supply Chain
Alok Sonig, Senior Vice President & India Business Head (Generics)
K Singh, Chief Compliance Officer, Company Secretary
Allan Oberman, Non-Executive Independent Director
J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives
Abhijit Mukherjee, COO
Anil Namboodiripad, Global Head of Proprietary Products
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCRE
SANJAY SHARMA, Global Head of Manufacturing
Sridar Iyengar, Non-Executive Independent Director
Ganadhish Kamat, Executive Vice President and Global Head-Quality
Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council
Vivek Mittal, Interim Compliance Officer, General Counsel
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI
Kalpana Morparia, Non-Executive Independent Director
J Moreau, Non-Executive Independent Director
Saunak Savla, IR Contact Officer
Deepak MBA, CEO Council
Ashok Ganguly, Non-Executive Independent Director
Anupam Puri, Non-Executive Independent Director
MBA MBA, CEO Council
Mukesh Rathi, Chief Digital and Information Officer

RDY Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dr Reddys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Dr Reddys in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Dr Reddys' short interest history, or implied volatility extrapolated from Dr Reddys options trading.

Currently Active Assets on Macroaxis

When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for RDY Stock analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.103
Dividend Share
40
Earnings Share
3.75
Revenue Per Share
272.4618
Quarterly Revenue Growth
0.066
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.